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Abstract
Background: As tumor antigen-specific CD4
+ T cells can mediate strong therapeutic anti-tumor responses in melanoma
patients we set out to establish a comprehensive screening strategy for the identification of tumor-specific CD4
+ T cell
epitopes suitable for detection, isolation and expansion of tumor-reactive T cells from patients.
Methods and Findings: To scan the human melanoma differentiation antigens TRP-1 and TRP-2 for HLA-DRB1*0301-restricted
CD4
+ T cell epitopes we applied the following methodology: Splenocytes of HLA-DRB1*0301-transgenic mice immunized with
recombinant adenovirus encoding TRP-1 (Ad5.TRP-1) or TRP-2 (Ad5.TRP-2) were tested for their T cell reactivity against
combinatorial TRP-1- and TRP-2-specific peptide libraries. CD4
+ T cell epitopes thus identified were validated in the human
system by stimulation of peripheral blood mononuclear cells (PBMC) from healthy donors and melanoma patients. Using this
strategy we observed that recombinant Ad5 induced strong CD4
+ T cell responses against the heterologous tumor antigens. In
Ad5.TRP-2-immunized mice CD4
+ T cell reactivity was detected against the known HLA-DRB1*0301-restricted TRP-260–74
epitope and against the new epitope TRP-2149–163. Importantly, human T cells specifically recognizing target cells loaded with
theTRP-2149–163-containinglibrarypeptideorinfectedwithAd5.TRP-2wereobtainedfromhealthyindividuals,andshorttermin
vitro stimulation of PBMC revealed the presence of epitope-reactive CD4
+ T cells in melanoma patients. Similarly, immunization
of mice with Ad5.TRP-1 induced CD4
+ T cell responses against TRP-1-derived peptides that turned out to be recognized also by
human T cells, resulting in the identification of TRP-1284–298 as a new HLA-DRB1*0301-restricted CD4
+ T cell epitope.
Conclusions: Our screening approach identified new HLA-DRB1*0301-restricted CD4
+ T cell epitopes derived from
melanoma antigens. This strategy is generally applicable to target antigens of other tumor entities and to different HLA
class II molecules even without prior characterization of their peptide binding motives.
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Introduction
Tumors,asaltered self, expressa proteinrepertoire differentfrom
normal cells that can be specifically recognized by T lymphocytes of
the host’s immune system. Accordingly, infiltration of tumors by T
lymphocytes has been demonstrated for different tumor entities to
be associated with improved prognosis [1–4], suggesting that tumor
antigen-specific T cell responses have a strong impact on the
outcome of the disease. Of the two tumor-specific T lymphocyte
subsets, CD8
+ T cells recognize tumor antigen-derived peptides in
the context of MHC class I molecules whereas CD4
+ T cells
respond to peptide-MHC class II complexes. Due to their capability
to directly kill malignant cells, cytotoxic CD8
+ T lymphocytes
(CTL) have long been defined as the ultimate effector cells in anti-
tumor immunity. Indeed, adoptive transfer of tumor antigen-
specific autologous CTL improved the clinical outcome of stage IV
melanoma patients [5–7]. However, the beneficial potential of
adoptively transferred T cells turned out to be more pronounced
if autologous tumor infiltrating lymphocytes (TIL) instead of iso-
lated CTL clones were administered to patients, an effect that
was attributed to tumor-specific CD4
+ T cells present among the
TIL infused [8–10]. In fact, evidence is accumulating that CD4
+ T
cells can actually induce strong anti-tumor immune responses, as
recently demonstrated in mice and humans [11–16].
How CD4
+ T cells mediate anti-tumor immunity is still under
investigation, but it appears that the underlying mechanisms are
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+ T cells
essentially sustain the anti-tumor activity of CTL by licensing
dendritic cells (DC) to effectively prime CTL [17,18] or by
maintaining profound CTL memory [19], as well as by direct
stimulation of CTL [20]. Furthermore, recent studies demonstrate
that adoptively transferred CD4
+ T cells can induce tumor
rejection also independently of CD8
+ T cells. This indirect process
was shown to be based on the release of cytokines by CD4
+ T cells
[12] and on the CD4
+ T cells’ interaction with other immune cells
such as macrophages and NK cells [21]. Notably, Quezada et al.
and Xie et al. recently showed that naı ¨ve tumor antigen-specific
CD4
+ T cells, upon adoptive transfer into lymphopenic mice, can
even differentiate into cytotoxic T cells that eradicate large
established tumors [11,14]. These results are also in accordance
with a clinical study describing the complete remission of stage IV
metastatic melanoma upon adoptive transfer of ex vivo expanded
autologous tumor antigen-specific CD4
+ T cells [15].
Thus, tumor antigen-specific CD4
+ T cells essentially contribute
to anti-tumor immunity which has strongly stimulated the interest
in the identification of their target epitopes. The widely applied
‘‘reverse immunology’’ approach for epitope identification is based
on in silico prediction of antigen-derived peptides with high binding
affinities to a specific MHC molecule. The candidate sequences
are then synthesized and loaded onto DC for in vitro priming of
autologous CD4
+ T cells. Finally, peptide-reactive T cells are
employed to demonstrate generation and presentation of the
corresponding epitope by antigen-loaded target cells. Unfortu-
nately, most allele-specific peptide binding motifs of MHC class II
molecules are highly degenerated making the algorithm-based in
silico prediction of potential CD4
+ T cell epitope sequences still
speculative. Thus, after extensive T cell culture only a subgroup of
predicted peptides can be verified as natural epitopes. Though
different CD4
+ T cell epitopes from tumor antigens such as CEA
[22], p53 [23] or TRP-2 [24] have been defined by in silico
prediction, we set out to overcome the drawbacks of this strategy
by setting up a comprehensive screening approach based on the
immunization of HLA-transgenic mice with recombinant adeno-
virus encoding human melanoma antigens and subsequent
scanning of the T cell responses in vitro with the help of
combinatorial antigen-specific peptide libraries. This approach
allowed us to directly concentrate our efforts on naturally
processed tumor antigen-specific epitopes presented by a given
MHC class II restriction element. As target antigens the
melanoma differentiation antigens TRP-1 and TRP-2 were
chosen, since both proteins are known to be frequently recognized
by CD8
+ T cell in melanoma patients [25,26]. In fact, targeting of
TRP-1 by adoptively transferred CD4
+ T cells was recently shown
to mediate eradication of large established tumors in mice [14].
Materials and Methods
Ethics Statement
All studies on human material were approved by the
institutional review board of the University Medicine Mannheim
(Mannheim, Germany). Blood samples from healthy donors and
melanoma patients were collected upon written consent. Animal
experiments were approved by the internal ethics committee of the
German Cancer Research Center and by the District Government
in Karlsruhe, Germany (approval ID 35-9185.81/G-86/04).
HLA-DRB1*0301-transgenic mice
HLA-DRB1*0301-transgenic (HLA-DR3tg) mice expressing
the HLA-DRB1*0301 molecule on an IA
0/0 H2 background
were kindly provided by Chella David (Mayo Medical School,
Rochester MN) [27]. Transgene expression was confirmed by flow
cytometric analysis of peripheral blood lymphocytes (PBL) stained
with a FITC-conjugated, pan HLA-DR-specific monoclonal anti-
body L243 (Becton Dickinson, Heidelberg, Germany). Mice were
housed under SPF conditions in individually ventilated cages
within the animal facility of the German Cancer Research Center.
Peptide libraries and synthetic candidate peptides
TRP-1- and TRP-2-specific peptide libraries consisting of 66
and 64 peptides (20mers) respectively, overlapping by 12 amino
acids, were purchased from JPT (JPT Peptide Technologies,
Berlin, Germany) and Mimotopes (Mimotopes, Clayton, Austra-
lia). Library peptides were resolved in DMSO at a concentration
of 20 or 50 mg/ml and were kept frozen at 220uC until use.
Combinatorial peptide libraries specific for TRP-1 and TRP-2
were established by setting up 16 library peptide pools (X1–X8
and Y1–Y8), each pool consisting of eight peptides combined in
such a way that each individual library peptide was shared once by
two particular pools (Fig. 1A) [28]. The two C-terminal peptides of
the TRP-1-specific peptide library corresponding to TRP-1513–532
and TRP-1518–537 (peptides #65 and #66) respectively, were
included as separate peptides in the assays. Candidate peptides
selected by library screening were synthesized by Fmoc chemistry
and were FPLC-purified at the peptide synthesis core facility of
the DKFZ.
Recombinant adenoviruses
E1- and E3-deleted replication-deficient, recombinant adenovi-
ruses encoding human TRP-2 (Ad5.TRP-2) or EGFP (Ad5.EGFP)
were described previously [29,30]. The adenoviral vector ex-
pressing human TRP-1 (Ad5.TRP-1) was generated through Cre-
lox recombination as described for Ad5.TRP-2 [29]. TRP-1
expression was verified by indirect immunostaining of Ad5.TRP-
1-infected human HEK293T cells (multiplicity of infection (MOI)
=1) using supernatant of the TRP-1-specific hybridoma TA99,
kindly provided by Alan N. Houghton (Sloan Kettering-Institute,
New York, NY), together with a goat anti-mouse-Cy3 conjugate
(BD Pharmingen, Heidelberg, Germany). Recombinant adenovi-
ruses were amplified in HEK293T cells and were subsequently
purified by CsCl gradient centrifugation as described before [29].
Immunization of HLA-DR3tg mice and analysis of murine
T cell responses in vitro
Mice were immunized by intraperitoneal (i.p.) injection of
5610
8 plaque forming units (pfu) Ad5.TRP-2 or Ad5.TRP-1. As a
control, Ad5.EGFP was injected at the same dose. Two weeks
later, spleen cells from immunized mice were tested for ex vivo
recognition of TRP-2- or TRP-1-specific peptide library pools by
interferon (IFN)-c ELISpot assays using aMEM (Sigma) supple-
mented with 10% FCS (Biochrom, Berlin, Germany), 2 mmol/l
glutamine (Gibco-Invitrogen, Karlsruhe, Germany), and 50 mmol/l
2-mercaptoethanol. The pool concentration of each library peptide
was 1.5 mg/ml. The same concentrations were used when TRP-
2-specific library peptides were screened individually, whereas
individual TRP-1 library peptides were used at a concentration of
5 mg/ml. For in vitro expansion of peptide-specific T cells, sple-
nocytesfrom immunizedmicewere incubatedin the presence of the
selected peptides (5 mg/ml). After 6 days, 2.5% (v/v) supernatant of
conA-stimulated rat spleen cell cultures was added as a source of
interleukin (IL)-2. Two days later, T cell responses against the
cognate peptides were analyzed by intracellular IFN-c staining,
using a cytokine staining kit (BD Pharmingen) according to the
manufacturer’s instructions in combination with goat anti-mouse
CD4
+ T Cell Epitopes
PLoS ONE | www.plosone.org 2 November 2010 | Volume 5 | Issue 11 | e14137CD4- and CD8-specific monoclonal antibody conjugates (BD
Pharmingen).
IFN-c ELISpot assays with murine spleen cells
IFN-c ELISpot assays were performed using Multiscreen ELI-
Spot plates (Millipore, Schwalbach, Germany) coated with 1 mg/ml
rat anti-mouse IFN-c capture antibody (R4-6A2; Becton Dickinson)
for 1 to 2 h at 37uC. After blocking, 10
6 spleen cells were co-
incubated together with library peptide pools or individual peptides
in a total volume of 200 ml per well for 16–18 h in the above
mentioned medium. After washing, wells were incubated with
2 mg/ml biotinylated rat anti-mouse IFN-c antibody (XMG1.2;
Becton Dickinson) for 2 h at 4uC. Again after washing, plates were
incubated with avidin-conjugated alkaline phosphatase (Becton
Dickinson) for 30 min. IFN-c-specific spots were developed by
adding 100 ml BCTP/NBT (Sigma, Deisenhofen, Germany) into
each well. Reaction was stopped after 2–4 min by rinsing the wells
with distilled water. Spots were counted using an ELISpot reader
(AID, Strassberg, Germany).
Detection of peptide-specific human T cell responses
The HLA genotype of PBMC from healthy donors and patients
was determined by high-resolution PCR typing. For analysis of
specific T cell responses, frozen PBMC from HLA-DRB1*0301
+
healthy donors and HLA-DRB1*03
+ patients were thawed and
cultured overnight in T cell medium consisting of RPMI 1640/
HEPES/2 mM glutamine supplemented with 10% human AB
serum (PAA Laboratories), 100 U/ml penicillin, 100 mg/ml
streptomycin. Total PBMC or PBMC depleted of CD25
+ T cells
with anti-CD25-coated microbeads (Miltenyi Biotec, Bergisch
Gladbach, Germany) according to the manufacturer’s instructions,
were seeded at 2610
6 cells/ml per well of a 24-well plate in T cell
Figure 1. Combinatorial peptide library screening allows detection of individual library peptides containing TRP-2-specific T cell
epitopes. A, Composition of the TRP-2-specific library peptide pools X1 to X8 and Y1 to Y8 used for combinatorial screening of specific T cell
responses ex vivo. Individual library peptides determined by combinatorial screening are highlighted. B, Spleen cells from HLA-DR3tg mice injected
i.p. with 5610
8 pfu Ad5.TRP-2 or Ad5.EGFP (2 mice per group) were screened ex vivo by IFN-c ELISpot assay for recognition of TRP-2-specific library
peptide pools. T cell responses of two control mice (Ad5.EGFP) and two TRP-2-immunized mice (Ad5.TRP-2) are represented as individual columns in
the diagram. Reactivity against two controls, the H2-K
b-restricted CD8
+ T cell epitope TRP-2180-188 and the HLA-DRB1*0301-restricted CD4
+ T cell




+ T Cell Epitopes
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were added at a concentration of 10 mg/ml, control cells were left
without peptide. Half of the supernatant was exchanged every 4
days. After 17 and 25 days, cells were harvested and screened for
peptide-specific reactivity in an IFN-c ELISpot assay as described
before [31]. Briefly, 10
5 PBMC/well were incubated with peptide
(5 mg/ml) in a 96-well microfiltration plate coated with anti-IFN-c
mAb (1-D1K; Mabtech, Stockholm, Sweden). After 16 h, second-
ary biotinylated anti-human IFN-c mAb (7-B6-1; Mabtech) was
added to the wells and captured cytokine was detected with avidin-
peroxidase (Vectastain Elite Kit; Vector Laboratories, Burlingame,
CA) and AEC substrate (Sigma, Deisenhofen, Germany). Spots
were imaged and counted using the ELISpot Bioreader 3000 (Bio-
Sys, Karpen, Germany). All determinations were performed at least
in duplicates. The data are presented as mean numbers of IFN-c
spots per 10
5 cells.
Generation of peptide-specific human T cell lines and
specificity analysis
T cells specific for TRP-2 peptide #19 were primed in vitro by
stimulation of total PBMC from healthy individuals with autologous
peptide-loaded DC and repeated restimulation as described
previously [24]. Peptide-stimulated CD4
+ T cells were purified
with anti-CD4-specific mAb coated microbeads (Miltenyi Biotec),
according to the manufacturer’s protocol. Reactivity of CD4
+ T
cells (10
5) was determined against peptide-loaded or adenovirus-
infected target (stimulator) cells (5610
4)i nI F N - c ELISpot assays as
described above. For peptide loading, stimulators (T2.DR3 cells
[24], kindly provided by Frank Momburg, German Cancer
Research Center, Heidelberg, Germany) were incubated with
5 mg/ml peptide for 2 h. To obtain virus-infected target cells,
autologous PBMC depleted of CD3
+ T cells (CD3
2 PBMC) with
anti-CD3-specific mAb coated microbeads (Miltenyi Biotec) were
infected overnight with Ad5.TRP-2 or Ad5.EGFP (MOI=100). All
determinations were done at least in duplicates. The data are
presented as mean spot numbers per 10
5 responder cells.
CD4
+ T cells specific for TRP-1284–298 were obtained after short
term peptide stimulation of PBMC from patient VHP. Therefore,
PBMC were stimulated once with peptide TRP-1284–298 (10 mg/
ml) and seeded at 2610
6 cells/ml per well of a 24-well plate in T
cell medium plus cytokines. After 25 days, CD4
+ T cells were
purified from PBMC and reactivity of T cells against peptide-
loaded T2.DR3 target cells or infected autologous CD3
2 PBMC
was determined, as described above. Furthermore, responses of
TRP-1284–298-specific CD4
+ T cells to the following melanoma cell








+) as well as against virus-infected Ma-Mel-
103b cells. TRP-1 and HLA-DR expression by melanoma cells
was determined by quantitative RT-PCR and flow cytometry,
respectively (data not shown).
Results
Screening for TRP-2-specific T cell responses in
Ad5.TRP-2-immunized HLA-DR3tg mice
Applying the ‘‘reverse immunology’’ approach we previously
identified TRP-260–74 as a HLA-DRB1*0301-restricted CD4
+ T
cell epitope [24]. In order to establish a more comprehensive
screening strategy, we developed an approach based on the
antigen-specific immunization of HLA-DR3tg mice with recom-
binant adenovirus for in vivo induction of strong CD4
+ T cell
responses that were subsequently analyzed in vitro for their
specificity against a peptide library covering the entire antigen
sequence.
Therefore, HLA-DR3tg mice were injected with recombinant
adenovirus encoding human TRP-2 (Ad5.TRP-2) or with
recombinant adenovirus encoding EGFP (Ad5.EGFP). After 14
days, spleen cells from immunized mice were analyzed ex vivo in an
IFN-c ELISpot assay for their reactivity against a TRP-2-specific
peptide library. The library consisted of a total of 64 overlapping
20mer peptides, covering the complete TRP-2 protein sequence.
These peptides were combined in 16 peptide pools X1–X8 and
Y1–Y8, whose composition was designed in a way that each pool
consisted of 8 peptides and that each individual peptide was shared
by two particular pools, allowing rapid identification of the epitope
containing library peptide (Fig. 1A) [28]. We found that the TRP-
2 peptide pools X1, X5 and X8 together with Y3, Y6, Y7 and Y8
were recognized by splenocytes from Ad5.TRP-2-immunized
mice, whereas no reactivity was observed in case of Ad5.EGFP-
treated animals (Fig. 1B). The twelve library peptides shared by
the recognized pools, highlighted in Fig. 1A, were thus considered
as potential epitope containing candidates and were subjected to
further analysis. Notably, mice injected with Ad5.TRP-2 recog-
nized two control peptides, the H2-K
b-restricted CD8
+ T cell
epitope TRP-2180–188 [32] and the HLA-DRB1*0301-restricted
CD4
+ T epitope TRP-260–74 [24], demonstrating that immuniza-
tion of mice with Ad5.TRP-2 should provide a solid basis for the
identification of yet unknown T cell epitopes.
Identification of TRP-2-derived CD4
+ T cell epitopes in
HLA-DR3tg mice
In a subsequent experiment the twelve candidate peptides
determined above were tested individually for their recognition
by splenocytes from Ad5.TRP-2-immunized HLA-DR3tg mice
(Fig. 2A). We found that the four candidate peptides (#8, #19,
#22, #23) could stimulate IFN-c secretion by splenocytes from
Ad5.TRP-2-immunized recipients but not from Ad5.EGFP-
treated animals. Thus, the number of potential epitope containing
library peptides could be minimized from initially 64 to 4 by two
sequential immunization steps.
The four library peptides #8, #19, #22 and #23 were
subsequently entered into the SYFPEITHI data base for




+ T cell epitopes, respectively [33]. Library peptide
#8 was proposed to represent a CD4
+ T cell target sequence
corresponding to the known TRP-260–74 epitope, previously
identified in our own studies (Fig. 2B). Peptide #19 was predicted
to harbour a so far unknown HLA-DRB1*0301-restricted epitope
TRP-2149–163. Library peptides #22 and #23 appeared as
particular candidates since these peptides containing the known
H2-K
b-restricted CTL epitope TRP-2180–188 were also predicted
to cover a CD4
+ T cell epitope (TRP-2177–191). Notably, the data
base predicted thirteen additional candidates as potential HLA-
DRB1*0301-restricted epitopes with relatively high prediction
scores of .21 (not shown). However, except for peptide TRP-260–74
none of the library peptides containing the respective predicted
epitope sequences was recognized by the spleen cells of immunized
HLA-DR3tg mice (Fig. 1 and data not shown).
In order to prove recognition of the candidate peptides by CD4
+
T cells, shortened synthetic 15mers derived from the 20mer library
peptides were used to restimulate splenocytes from Ad5.TRP-2-
immunized HLA-DR3tg mice in vitro. Performing intracellular IFN-
c stainings it was found that peptides TRP-260–74 and TRP-2149–163
derived from library peptides #8 and #19, respectively, clearly
induced IFN-c secretion by CD4
+ spleen cells (Fig. 2C). Among
total spleen cells of Ad5.TRP-2-immunized mice 0.21% and 0.23%
CD4
+ T Cell Epitopes
PLoS ONE | www.plosone.org 4 November 2010 | Volume 5 | Issue 11 | e14137Figure 2. Phenotypic analysis of TRP-2-specific T cell responses induced in Ad5.TRP-2-immunized HLA-DR3tg mice. A, Spleen cells
from HLA-DR3tg mice injected i.p. with 5610
8 pfu Ad5.TRP-2 or Ad5.EGFP (2 mice per group) were screened ex vivo by IFN-c ELISpot assay for
reactivity against individual TRP-2-specific library peptides determined by combinatorial analysis. T cell responses of two control mice (Ad5.EGFP) and
two TRP-2-immunized mice (Ad5.TRP-2) are represented as individual columns in the diagram. Error bars show standard error of the mean.
Experiments were performed three times, yielding similar results. B, Selected TRP-2-derived library peptides #8, #19, #22 and #23 are indicated by
amino acid (aa) positions and aa sequence. Peptides were analyzed in silico by the SYFPEITHI algorithm [33] for the presence of predicted HLA-
DRB*0301 binding sequences (underlined). Prediction scores for HLA-DRB1*0301-restricted epitopes are listed on the right. Known HLA-DRB1*0301-
restricted CD4
+ T cell epitopes are typed in bold and the H2-K
b-restricted CTL epitope TRP-2180–188 is written in italics. C, HLA-DR3tg mice received i.p.
injections of 5610
8 pfu Ad5.TRP-2 or Ad5.EGFP (3 mice per group). Two weeks later spleen cells from infected mice were harvested and stimulated
CD4
+ T Cell Epitopes
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+ IFN-c
+ T cells were detected on average upon stimulation
with TRP-260–74 and TRP-2149–163, respectively, whereas only
around 0.025% double positive spleen cells were found in cultures
from control mice. In contrast, library peptides #22 and #23
induced a profound CD8
+ T cell response, most likely due to the
CTL epitope TRP-2180–188 contained within these peptides, but
failed to stimulate CD4
+ T cells (Fig. 2B, data not shown). Thus,
applying the combinatorial antigen-specific peptide library screening
approach, peptide #19 was found to contain the new TRP-2149–163
epitope recognized by CD4
+ T cells from HLA-DR3tg mice.
CD4
+ T cells from melanoma patients respond to the
TRP-2149–163 epitope
Next, we asked whether human CD4
+ T cells would also respond
to library peptide #19. Therefore, we set out to generate a peptide
#19-specific CD4
+ Tc e l ll i n eb yin vitro priming of T cells from a
HLA-DRB1*0301
+ healthy donor with peptide-loaded autologous
DC. After the second invitrorestimulation, CD4
+T cellspecificity was
tested against T2.DR3 cells loaded with peptide #19 versus non-
loaded target cells. Performing IFN-c ELISpot assays we observed
that the CD4
+ T cells responded to T2.DR3 target cells only in the
presence of peptide #19 (Fig. 3A). Importantly, these T cells reacted
specifically also against autologous stimulator cells infected with
Ad5.TRP-2 but not against Ad5.EGFP-infected stimulators (Fig. 3A).
Thus, we concluded that peptide #19, identified as a CD4
+ Tc e l l
epitopecontaininglibrarypeptideinHLA-DR3tgmice,alsoprovides
a naturally processed epitope in humans.
Based on this result we screened PBMC from six HLA-
DRB1*03
+ melanoma patients (GA, ME, PK, VHP, SA, BH) and
four HLA-DRB1*0301
+ healthy donors (BF1, BF3, BF4, BF5) for
the presence of peptide #19-reactive T cells. Therefore, PBMC
stimulated once in vitro with peptide #19 for 17 days were tested
for their reactivity against library peptide #19 in comparison to
the shortened variant TRP-2149–163. Interestingly, PBMC from
patient BH showed specific recognition of both peptides, whereas
none of the healthy donors reacted specifically under these
conditions (Fig. 3B, C; left panel).
Since depletion of CD25
+ regulatory T cells (Treg) from PBMC
has been demonstrated to enhance detection of antigen-specific
CD4
+ T cell responses [34], we additionally stimulated CD25-
depleted PBMC from melanoma patients and healthy individuals
with library peptide #19. Remarkably, detection of peptide #19
reactivity was very much improved, reflected by the enhanced
IFN-c response of CD4
+ T cells from patient BH and by the fact
that peptide specific T cells now became detectable also in case of
healthy donor BF5 (Fig. 3B, C; right panel). In all cases, T cell
cultures recognizing library peptide #19 showed cross-reactivity
also against the shortened peptide variant TRP-2149–163. Similarly,
cross-reactivity was observed when peptide TRP-2149-163 was used
for primary in vitro stimulation of PBMC (data not shown). Thus,
peptides #19 and TRP-2149–163 can stimulate specific CD4
+ T
cells that are mutually cross-reactive, suggesting that TRP-2149–163
is a HLA-DRB1*0301-restricted T cell epitope also in humans.
Screening for TRP-1-specific T cell responses in
Ad5.TRP-1-immunized HLA-DR3tg mice
In addition to TRP-2 we applied the above described screening
strategy also to the identification of CD4
+ T cell epitopes from the
differentiation antigen TRP-1. The new recombinant Ad5.TRP-1
mediated strong TRP-1 expression in infected HEK293T cells as
confirmed by immunofluorescence microscopy using the TRP-1-
specific monoclonal antibody TA99 (data not shown). This virus
was then used for immunization of HLA-DR3tg mice whose
splenocytes were subsequently tested for their reactivity against a
TRP-1-specific peptide library consisting of 66 overlapping
20mers. Library peptides #1–#64 were combined in 16 pools
(X1–X8 and Y1–Y8) as described for TRP-2 (Fig. 4A). The two
additional peptides #65 and #66 were tested separately in initial
screening experiments. However, since none of these two peptides
elicited specific IFN-c secretion among spleen cells (data not
shown) they were excluded from further assays. Screening of the
peptide library revealed that peptide pools X2, X4, X8 and Y1,
Y4, Y7, Y8 specifically stimulated spleen cells of both Ad5.TRP-1-
immunized mice but not of Ad5.EGFP-treated animals (Fig. 4B),
leading to the selection of 12 single candidate peptides highlighted
in Fig. 4A.
Identification of TRP-1-derived CD4
+ T cell epitopes in
HLA-DR3tg mice
Analysis of the individual candidates from the TRP-1 peptide
library demonstrated that peptides #8, #9, #36 and #47
specifically induced cytokine release by splenocytes of Ad5.TRP-1-
immunized HLA-DR3tg mice (Fig. 5A). Subsequent in silico
analysis of these peptides predicted library peptide #9 to contain a
HLA-DRB1*0301-restricted CD4
+ T cell epitope encompassing
TRP-165–79 (Fig. 5B), partly present also within the sequence of
library peptide #8. Within library peptide #36 the sequence
TRP-1285–299 was predicted to represent a HLA-DRB1*0301-
restricted CD4
+ T cell epitope. Library peptide #47 was again an
exceptional candidate predicted to contain a CD4
+ T cell epitope
(score 20) as well as a nonamer (TRP-1374–382) perfectly fitting the
H2-D
b binding motif [35] with a score of 26 [33].
In order to define the T cell subset responding to the candidate
peptides we performed intracellular IFN-c stainings on spleen cells
from HLA-DR3tg mice immunized with Ad5.TRP-1 or
Ad5.EGFP. Stainings were performed after one round of in vitro
restimulation with candidate peptide epitopes. In these assays the
peptides TRP-164–78 and TRP-1284–298 were used instead of TRP-
165–78 and TRP-1285–298. The shift in the amino acid sequences
towards the N-terminus by one residue relative to the sequence
predicted by SYFPEITHI, was performed in order to improve the
peptide solubility without changing the natural sequence of the
protein.
Using this strategy, we observed that splenocyte cultures from
Ad5.TRP-1-immunized mice contained an average of 0.06% CD4
+
IFN-c
+ cells responding to TRP-164–78 versus 0.01% in case of
Ad5.EGFP-treated mice (Fig. 5C). The responses against peptide
TRP-1284–298 were much more pronounced. Cultures derived from
Ad5.TRP-1-immunized mice harboured around 0.18% CD4
+ IFN-
c
+ splenocytes whereas less than 0.01% double-positive cells were
detected incontrols.No CD8
+T cell responses were observed against
the two peptides. In contrast, CD8
+ T cell reactivity was detectable
with the candidate CTL-epitope TRP-1374–382 derived from library
peptide #47 among spleen cells of Ad5.TRP-1-immunized mice
(data not shown). Thus, the combinatorial screening approach
could also be successfully applied for the identification of HLA-
DRB1*0301-restricted CD4
+ T cell epitopes derived from TRP-1.
in vitro with the indicated peptides. After 6 days, splenocyte cultures were analyzed for the presence of peptide-reactive T cells by intracellular IFN-c
staining. Stained cells were analyzed by flow cytometry for the percentage of IFN-c
+ CD4
+ T cells. Error bars show standard error of the mean of three
immunized mice. Experiments were performed three times yielding similar results.
doi:10.1371/journal.pone.0014137.g002
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+ T cells from melanoma patients respond to the HLA-DRB1*0301-restricted epitope TRP-2149–163. A, PBMC from a HLA-
DRB1*0301
+ healthy donor were primed in vitro with autologous DC pulsed with library peptide #19. After two rounds of in vitro restimulation, CD4
+
T cells were tested against T2.DR3 target cells pulsed with library peptide #19 and for recognition of autologous CD3
+-depleted PBMC (CD3
2 PBMC)
infected with Ad5.TRP-2 or with control virus. One representative experiment out of two is presented. B, Total PBMC (left panel) or CD25
+-depleted
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+ T cells specific for TRP-1284–298 are present in PBMC
from melanoma patients
In the next step we analyzed peripheral blood cells from HLA-
DRB1*03
+ melanoma patients and HLA-DRB1*0301
+ normal
donors for the presence of TRP-164–78- and TRP-1284–298-specific
CD4
+ T cells. Therefore, PBMC either left untreated or depleted
of CD25
+ cells were stimulated once with the each peptide
individually. After a 25 day short term culture, cells were harvested
and analyzed for their peptide reactivity by IFN-c ELISpot assay
(Fig. 6). Under both conditions melanoma patient VHP showed
TRP-1284–298-specific T cell reactivity (Fig. 6A). However, TRP-
1284–298-specific T cell responses became detectable in healthy
donors only among CD25-depleted PBMC (Fig. 6B). In contrast to
TRP-1284–298, none of the cultures showed reactivity against
peptide TRP-164–78 (data not shown).
Finally, we set out to demonstrate the processing and
presentation of TRP-1284–298 by human target cells. We obtained
TRP-1284–298-specific CD4
+ T cells after short term peptide
Figure 4. Combinatorial peptide library screening allows detection of individual library peptides containing TRP-1-specific T cell
epitopes. A, Composition of the TRP-1-specific library peptide pools X1 to X8 and Y1 to Y8 used for combinatorial screening of specific T cell
responses ex vivo. Individual peptides determined by combinatorial screening are highlighted. B, Spleen cells from HLA-DR3tg mice injected i.p. with
5610
8 pfu Ad5.TRP-1 or Ad5.EGFP (2 mice per group) were screened ex vivo by IFN-c ELISpot assay for recognition of TRP-1-specific library peptide
pools. T cell responses of two control mice (Ad5.EGFP) and two Ad5.TRP-1-immunized mice are represented as individual columns in the diagram.
Error bars show standard error of the mean of duplicates. Experiments were performed four times, yielding similar results.
doi:10.1371/journal.pone.0014137.g004
PBMC (right panel) from six HLA-DRB1*03
+ melanoma patients and C, four HLA-DRB1*0301
+ healthy donors were incubated in vitro with library
peptide #19. After 17 days, cells were tested by IFN-c ELISpot assay for their reactivity against library peptide #19 or the epitope TRP-2149–163. All
determinations were performed at least in duplicates. Data are presented as mean numbers of IFN-c spots per 10
5 cells. Error bars show standard
error of the mean.
doi:10.1371/journal.pone.0014137.g003
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PLoS ONE | www.plosone.org 8 November 2010 | Volume 5 | Issue 11 | e14137Figure 5. Phenotypic analysis of TRP-1-specific T cell responses induced in HLA-DR3tg mice upon immunization with Ad5.TRP-1. A,
Spleen cells from HLA-DR3tg mice injected i.p. with 5610
8 pfu Ad5.TRP-1 or Ad5.EGFP (2 mice per group) were screened ex vivo by IFN-c ELISpot
assay for reactivity against selected TRP-1-derived library peptides. T cell responses of two control mice (Ad5.EGFP) and two Ad5.TRP-1-immunized
mice are represented as individual columns in the diagram. Error bars show standard error of the mean of duplicates. Experiments were performed
three times, yielding similar results. B, Selected TRP-1-derived library peptides #8, #9, #36 and #47 are indicated by amino acid (aa) positions and aa
sequence. Peptides were analyzed in silico by the SYFPEITHI algorithm for the presence of potential HLA-DRB*0301 binding sequences (underlined)
[33]. Prediction scores for HLA-DRB1*0301-restricted epitopes are listed on the right. The potential H2-restricted CTL epitope TRP-1374–382 is given in
italics. C, Spleen cells of HLA-DR3tg mice injected i.p. with 5610
8 pfu Ad5.TRP-1 or Ad5.EGFP (3 mice per group) were analyzed for the presence of
peptide-reactive T cells by intracellular IFN-c staining after one round of in vitro re-stimulation with the indicated peptides. Note: The amino acid
sequence of these peptides was shifted towards the N-terminus by one residue relative to the predicted epitope sequence. Stained cells were
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HLA-DRB1*0301-restricted activity of the CD4
+ T cell line was
demonstrated by the recognition of T2.DR3 target cells pulsed
with antigenic peptide (Fig. 7A). By coincubation of TRP-1284–298-
specific CD4
+ T cells with infected autologous target cells, it
turned out that Ad5.TRP-1-infected target cells, in contrast to
Ad5.EGFP-infected control cells, strongly induced IFN-c secretion
among TRP-1284–298-specific CD4
+ T cells, demonstrating
processing and presentation of the respective epitope by human
targets (Fig. 7A). In addition, the TRP-1284–298-specific CD4
+ T
cell line was used to investigate if human melanoma cell lines could
serve as stimulatory targets. Among the melanoma cell lines
Figure 6. Detection ofTRP-1284–298 reactiveCD4
+ Tcells inmelanomapatients. Total PBMC (left panel) or CD25
+-depleted PBMC (right panel)
from five HLA-DRB1*03
+ melanoma patients (A) and four HLA-DRB1*0301
+ healthy donors (B) were stimulated in vitro with peptide TRP-1284–298. After
25 days, PBMC were tested for their peptide reactivity by IFN-c ELISpot assay. All determinations were performed at least in duplicates. The data are
presented as mean numbers of IFN-c spots per 10
5 cells. Error bars show standard error of the mean.
doi:10.1371/journal.pone.0014137.g006
analyzed by flow cytometry for the percentage of IFN-c
+ CD4
+ T cells. Error bars show standard error of the mean of three immunized mice.
Experiments were performed twice yielding similar results.
doi:10.1371/journal.pone.0014137.g005
CD4
+ T Cell Epitopes
PLoS ONE | www.plosone.org 10 November 2010 | Volume 5 | Issue 11 | e14137tested we found that Ma-Mel-108 cells expressing both, HLA-
DRB1*0301 and TRP-1, were recognized. In contrast, melanoma
cells lines expressing HLA-DRB1*0301 while lacking TRP-1, like
Ma-Mel-103b as well as HLA-DRB1*0301
2 melanoma cell lines
expressing TRP-1, such as Ma-Mel-153, were ignored (Fig. 7B).
Notably, infection of melanoma cell line Ma-Mel-103b with
Ad5.TRP-1 turned this cell line into a susceptible target for TRP-
1284–298-specific CD4
+ T cells (Fig. 7C). Taken together, these
results demonstrate, that TRP-1284–298 can be presented by
different HLA-DRB1*0301
+, TRP1
+ target cells, thus representing
a new CD4
+ T cell epitope.
Discussion
The role of CD4
+ T cells in anti-tumor immunity has long been
restricted to their helper function in primary activation and
maintenance of antigen-specific cytotoxic CD8
+ T cell responses
[17–19]. However, several mouse studies point to additional roles
of CD4
+ T cells in tumor control. Adoptively transferred tumor
antigen-specific CD4
+ T cells have been demonstrated to mediate
dormancy or regression of tumors [12,16,21], even eradication of
large established tumor masses was observed [11,13,14]. In several
cases this was shown to be an indirect effect mediated by cytokines
Figure 7. TRP-1284–298 represents a HLA-DRB1*0301-restricted CD4
+ T cell epitope processed by human target cells. PBMC from
melanoma patient VHP were stimulated once with peptide TRP-1284–298 (10 mg/ml). After 25 days, selected CD4
+ T cells were tested for their reactivity
against different target cells by IFN-c ELISpot assay. A, Recognition of T2.DR3 target cells pulsed with peptide TRP-1284–298 and autologous CD3
+-
depleted PBMC (CD3







+) and C, against Ma-Mel-103b
cells infected with Ad5.TRP-1 or control virus is presented. A–C, One representative out of two to three independent experiments is given. Error bars
show standard error of the mean.
doi:10.1371/journal.pone.0014137.g007
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+ T cells [12,16] and by their interaction with
other immune cells like macrophages and NK cells [12,21].
However, studies by two independent groups demonstrated that
murine CD4
+ T cells specific for TRP-1, upon adoptive transfer
into a lymphopenic host, differentiated into cytolytic, IFN-c
secreting effectors [11,14] that directly killed MHC class II-
positive B16 melanoma cells [11]. Interestingly, MHC class II
surface expression on human melanoma cells has been described
to be associated with good prognosis [36], suggesting that
endogenous tumor antigen-specific CD4
+ T cells might become
activated by tumor cells and exert their anti-tumor effects directly
or indirectly. Recently, the clinical relevance of adoptively
transferred tumor antigen-specific CD4
+ T cells was impressively
documented in a report describing the complete remission of stage
IV metastatic melanoma [15].
This obvious importance of CD4
+ T cells in tumor control has
strongly stimulated the interest in epitopes recognized by CD4
+ T
cells. We applied a comprehensive new methodology for epitope
identification based on the immunization of HLA-DR3tg mice
with recombinant adenovirus encoding human tumor antigens
and subsequent screening of the T cell responses in vitro with the
help of combinatorial antigen-specific peptide libraries. This
approach allowed us to directly focus on epitope containing
peptides within the peptide library, thereby avoiding unnecessary
consideration of in silico predicted, but finally irrelevant candidates.
Following this strategy we observed that Ad5.TRP-2 and
Ad5.TRP-1 readily induced antigen-specific CD4
+ T cell as well
as CD8
+ T cell responses, demonstrating that in principle our
approach is suitable for the identification of MHC class I- and
MHC class II-presented epitopes. Focusing on MHC class II, we
identified TRP-260–74 and TRP-2149–163 as target epitopes of
CD4
+ T cells in Ad5.TRP-2 immunized mice. We previously
found TRP-260–74 to be recognized also by CD4
+ T cells from
HLA-DR3tg mice injected with recombinant TRP-2 protein,
indicating that T cell responses against this epitope can be elicited
by different antigen formats [24]. Importantly, we confirmed
TRP-2149–163 to be naturally processed and presented also in the
human system, as already shown for TRP-260–74 [24], and we
could detect epitope-specific CD4
+ T cells among PBMC of both,
melanoma patients and healthy individuals. In case of TRP-1 we
identified TRP-164–78 and TRP-1284–298 as epitopes in HLA-
DR3tg mice. We could detect TRP-1284–298–specific CD4
+ T cell
responses also in the human system, both among healthy donors
and melanoma patients. However the frequency of responding
patients was low (20%, Fig. 6A) and healthy donors showed
reactivity against this epitope only upon depletion of CD25
+ T
cells, albeit only in two out of four individuals. We have not
investigated the reasons why only a minor fraction of individuals
responded to this epitope, but it appears conceivable that TRP-
1284–298–specific CD4
+ T cell responses being potentially self-
reactive might be kept in check by peripheral tolerance
mechanisms, such as Tregs, as described below. In the case of
the epitope TRP-164–78 we failed to detect specific CD4
+ T cell
reactivity, both in patients and in healthy donors. One possibility
for this observation might be deletion of TRP-164–78-specific T
cells by central or peripheral tolerance. Alternatively, the
frequency of TRP-164–78-specific T cells might have been too
low for detection by the applied techniques. Moreover, it cannot
be excluded that TRP-164–78-specific T cells might actually be
present which, however, secrete cytokines other than IFN-c, like
immunosuppressive IL-10 or TGF-b.
Interestingly, while T cell responses specific for TRP-1284–298
and TRP-2149–163 could be detected after short term peptide
stimulation in whole PBMC populations from patients, healthy
donors showed specific T cell reactivity only after depletion of
CD25
+ T cells. This is in accordance with previous studies
demonstrating that naı ¨ve antigen-specific CD4
+ T cells from
healthy donors are silenced by CD25
+ Treg cells while antigen-
experienced CD4
+ T cells of the memory phenotype, as they are
likely to be present also within whole PBMC from our patient
group, are less sensitive to suppression [37,38]. However, even
after CD25
+ Treg depletion, T cells specific for TRP-164–78 were
neither detected in PBMC from healthy individuals nor from
patients, which might be due to the above indicated reasons. On
the other hand, HLA-DR3tg mice, after immunization with
Ad5.TRP-1, as performed in our study, might be a source of TRP-
164–78-specific T cells, whose T cell receptors (TCR) could be
cloned to generate TCR-recombinant tumor-reactive CD4
+ T
cells for adoptive therapy. In case of CD8
+ T cells, this approach
has already been followed by Johnson et al., who cloned from
CD8
+ T cells of HLA-A*02-transgenic mice highly avid TCR
recognizing the human melanoma differentiation antigen gp100,
in order to generate recombinant human PBL for adoptive cellular
therapy of melanoma patients [39].
Collectively, we demonstrate for the first time that by strategic
combination of HLA class II-transgenic mice, immunization with
recombinant Ad5 and combinatorial antigen-specific peptide
library screening, CD4
+ T cell epitopes from melanoma
differentiation antigens can readily be defined, pointing to a
broad applicability of this approach to target antigens of other
tumor entities and to different HLA class II molecules even
without prior characterization of their peptide binding motives.
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